R&D Projects
8
+
Patents
150
+
Time to IND Filing
Fastest
in
2
years
R&D Investment in 2024
US$25
million
FBDB™
Advantages of Our Technology Platform
Synergistically Re-Activating of Innate and Adaptive Immune Systems Multi targets strategy to eliminate Tumor Cells
Blockade of SIRPα/CD47 Signaling Pathway
Blockade of PD-1/PD-L1 Signaling Pathway
Modulation of the Tumor Microenvironment (TME) to Further Activate Macrophages and T Cells
News
Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance
HanchorBio announced that its wholly owned subsidiary, FBD Biologics Limited, has received approval from the Taiwan Food and Drug Administration (TFDA) for the Investigational New Drug (IND) application for HCB303, a next-generation trispecific fusion protein featuring a differentiated TIGIT-Fc ligand-trap strategy.
Oct 30, 2026
Read more
HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HanchorBio announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
Oct 27, 2026
Read more
HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
HanchorBio announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
Oct 27, 2026
Read more
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.
Oct 22, 2026
Read more
HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment
HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.
Oct 19, 2026
Read more
HanchorBio Expands HCB101 Colorectal Cancer Program in Taiwan as Early 2L CRC Data Show 50% ORR and 100% DCR
HanchorBio today announced that the first patient in Taiwan has been dosed in the colorectal cancer (CRC)-specific cohort of its global Phase 1b/2a HCB101-201 study (NCT06771622), expanding the Company’s global development program in second-line metastatic CRC.
Oct 14, 2026
Read more
HanchorBio Expands Global Pharma Engagement at BioJapan 2026
HanchorBio announced its participation in BioJapan 2026 in Yokohama, Japan. The Company has scheduled more than 15 partnering meetings with regional and global pharmaceutical leaders to explore co-development and strategic collaboration opportunities across its proprietary Fc-based Designer Biologics (FBDB™) platform.
Oct 12, 2026
Read more
HanchorBio Advances HCB303 Global Clinical Development with Taiwan TFDA IND Submission Following US FDA Clearance
HanchorBio announced the submission of an Investigational New Drug (IND) to the Taiwan Food and Drug Administration (TFDA) for HCB303.
Oct 08, 2026
Read more
HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy
HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303. The clearance enables HanchorBio to initiate its Phase 1 first-in-human clinical trial.
Oct 03, 2026
Read more
HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day
HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
Sep 23, 2026
Read more
JOIN OUR TEAM
